Fosfomycin has emerged as a potential therapy for multidrug-resistant bacterial infections. In most European countries, the oral formulation is only approved as a 3 g single dose for treatment of uncomplicated cystitis. However, for the treatment of complicated systemic infections, this dose regimen is unlikely to reach efficacious serum and tissue concentrations. This study aims to investigate different fosfomycin-dosing regimens to evaluate its rationale for treatment of systemic infections. Serum concentration-time profiles of fosfomycin were simulated using a population pharmacokinetic model based on published pharmacokinetic parameter values, their uncertainty, inter-individual variability and covariates. The model was validated on published data and used to simulate a wide range of dosing regimens for oral and intravenous administration of fosfomycin. Finally, based on the minimum inhibitory concentration for E. coli, surrogate pharmacodynamic indices were calculated for each dosing regimen. This is the first population pharmacokinetic model to describe the oral pharmacokinetics of fosfomycin using data from different literature sources. The model and surrogate pharmacodynamic indices provide quantitative evidence that a dosing regimen of 6-12 g per day divided in 3 doses is required to obtain efficacious exposure and may serve as a first step in the treatment of systemic multi-drug-resistant bacterial infections.
| INTRODUCTION
Antibacterial resistance remains one of the major threats to human health, despite its identification as one of the worldwide priority conditions by the WHO over a decade ago. [1] [2] [3] Particularly alarming is the rise in number and spread of multi-drug resistant (MDR) bacterial strains and a poor pipeline of new Gram-negative antibiotics. [4] [5] [6] [7] To battle MDR bacteria strains, the reassessment and reintroduction of 'old' antibiotics have emerged as alternative solution to circumvent the long and costly process of developing new antibiotics. 8, 9 One of such 'old' antibiotics is fosfomycin, developed more than 40 years ago. 10 Fosfomycin is a broad spectrum antibiotic which exerts its bactericidal activity by irreversibly inhibiting the early stages of the bacterial cell wall synthesis.
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MDR Gram-negative bacteria are responsible for around twothirds of the deaths by MDR-bacterial infections in Europe. 6 Fosfomycin exhibits in vitro and in vivo antibacterial activity against a wide range of both Gram-positive and Gram-negative bacteria, including several MDR-strains. [12] [13] [14] [15] [16] [17] Even most of the extensively drug-resistant (XDR) Enterobacteriaceae strains still remain susceptible to fosfomycin, including those expressing extended-spectrum beta-lactamases (ESBL) or metallo-b-lactamases (MBL). [14] [15] [16] 18 In addition, fosfomycin has been suggested as add-on therapy for infections caused by MDR-P. aeruginosa, one of the main pathogens associated with nosocomial-acquired infections. 16, 17, 19 Fosfomycin has been marketed in different formulations including fosfomycin tromethamine for oral administration and fosfomycin disodium for intravenous administration. 20 In most European countries, only the oral formulation is available and approved as a single 3 g dose for the treatment of uncomplicated urinary tract infections (UTIs) in women. This single-dose regimen is not efficacious for the treatment of systemic MDR bacterial infections, making the prospective evaluation of new oral dosing regimens a necessity. A multiple-dose regimen of oral fosfomycin tromethamine has been proposed for the treatment of complicated UTIs, including those due to MDR-bacteria. 21, 22 However, more studies are urgently needed to determine the optimal oral dose regimen to achieve efficacious systemic exposure.
Few pharmacokinetic (PK) models for fosfomycin have been described in literature, which were developed on different study designs, limited numbers of subjects and different model structures. [23] [24] [25] [26] PK modeling techniques allow integration of different study designs, on the basis that despite study differences the underlying population pharmacokinetics are similar, as commonly applied in dose-regimen selection. 27 To assess the feasibility of a multiple oral-dose regimen with fosfomycin tromethamine for systemic infections, a combined PK model for intravenous and oral administration was built on PK parameters reported in literature in order to simulate various serum-concentration time profiles. In addition, surrogate pharmacodynamic indices were calculated, based on the minimum inhibitory concentration (MIC) representing the epidemiological cut-off value for E. coli, 28 to estimate its clinical efficacy.
2 | METHODS
| PK model
The structural model for intravenous administration was based on a previously reported two-compartment population PK model of fosfomycin, developed on 12 patients scheduled for abscess drainage. 25 The model was parameterized in terms of elimination rate constant (k e ), volumes of distribution for the central (Vc) and peripheral compartments (Vp) and intercompartmental clearance (Q). The rate and duration of infusion were parameterized by Q inf and t inf , respectively.
To include oral administration of fosfomycin tromethamine, the model was extended with a gastrointestinal-(GI) and a transit com- Figure 1 .
The two compartment PK model structure used for the simulations of fosfomycin multiple-dose regimens (black), together with the excluded enterohepatic recirculation (gray). CL, clearance; CMT, compartment with associated number; k10, the first-order loss prior to reaching CMT 2; k12, k23, k56, k61, rate constants between compartments; kb, biliary elimination; GI; gastrointestinal; Q, intercompartmental clearance; Q inf infusion rate constant; t inf , infusion time; TRANS, transit; Vc, central volume of distribution; Vp, peripheral volume of distribution Individual PK parameters were simulated according to Equation 1. 
where subscript LN refers to the log domain, and N refers to the normal domain. Subsequently, h TV was calculated according to Equation
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| Covariates
A mean-centered linear relationship between creatinine clearance (CL CR ) and clearance (CL) was reported, 25 and incorporated as such in the simulated clearance for the i th individual (CL i , Equation 5).
where CL TV is the literature derived mean population parameter with its uncertainty (Equation 4), CL CR,i is the creatinine clearance and g i the IIV for the i th individual. The CL CR,i and normalization factor (103) were obtained from Sauermann et al. 32 To simulate CL CR,i , samples were drawn from a distribution with a mean of 103 and standard deviation 41, which was limited between the minimal and maximal reported values. 
| Model validation
The validation of the PK models was performed by simulating previously published study designs and visually comparing the 90% prediction interval (PI) of the simulations to the observed data reported in literature. In short, the previously published study designs in healthy volunteers were, for intravenous administration, 8 doses of 500 mg every 6 hours 35 ; 500 mg in 5 min infusion 23 ; and 50 mg/kg bolus. 24 For single-dose oral administration, dosing regimens were 50 mg/kg, 2 g and 5 g. 36 Secondly, the lower 90% prediction interval (PI) of the simulated plasma concentration-time profiles was used, e.g., 95% of all subjects will have higher exposure compared to this PI.
3 | RESULTS
| PK Models
The contribution of enterohepatic recirculation on improvement of descriptive properties of the model proved to be marginal; the median concentrations and 90% PI did not differ substantially. The slight changes were considered to be of no clinical relevance. Secondly, as there is also no consistent proof for enterohepatic recirculation in literature, it was decided to exclude this PK property from the model. 
| Simulation of different multiple-dose regimens and calculation of PK/PD Indices
Different multiple-dose regimens after oral administration of fosfomycin were simulated using the validated PK model. Figure 4 shows the medians of the predicted PK profiles of 1000 subjects (qd), two times daily (bid) and three times daily (tid). The predicted medians of these different dose regimens as presented in Figure 5 show that the medians of all first doses reached serum concentrations above the MIC. For both dose groups, concentrations only maintain above the MIC for the entire duration of the day following tid dosing. As shown in Table 3 , a 2 g tid dose would also not suffice to reach a %T >MIC of 100%. Interestingly, the currently clinically approved 3 g single oral dose for UTIs may achieve efficacious concentrations in urine, however, it only achieves a %T >MIC of around 30% in serum. 
| DISCUSSION
This is the first population PK model to describe the oral pharmacokinetics of fosfomycin, using data from different literature sources.
The study provides quantitative evidence that an oral dosing regimen of 6-12 g per day divided in 3 doses is required to obtain serum concentrations above the MIC for at least 50% of the dose interval. This may serve as a first step in the treatment of systemic infections by MDR bacteria with a similar MIC compared to E.coli.
Model validation showed a slight bias in the description of literature data and overprediction of variability. The slight bias can be explained by the use of few subjects in the development of the literature models causing relatively high parameter uncertainty and IIV, which accumulates in large prediction intervals. Following intravenous simulation, late PK time points seem overestimated while for oral simulations time points after 15 hours seem underestimated, which may lead to bias in accumulation following multiple dosing regimens. In general, the reported population PK parameters used in our simulations were within the CI reported in a recent publication on intravenous fosfomycin infusion in critically ill patients. Compared to the volume of distribution in our simulations, the publication reports a relatively high volume of distribution, which the authors attest to pathophysiological changes in their critically ill patient population. 26 We acknowledge the quantitative and qualitative lack of data in literature, which is the case for many drugs that have been developed in the past. For this reason, we stress the importance of additional clinical data to ascertain whether oral fosfomycin may be used for the treatment of systemic.
The suggested daily oral doses of fosfomycin tromethamine to achieve an effective serum concentration exceed the currently This again stresses the need for more data.
The lack of PD data has also affected the clinical and PD breakpoints for MDR-bacterial infections from a regulatory perspective. In the case of fosfomycin tromethamine, the EUCAST has established clinical breakpoints for Enterobacteriaceae (Susceptible ≤32 mg/L and Resistant > 32 mg/L) which are only applicable to uncomplicated UTIs caused by Enterobacteriaceae, using a single dose of 3 g. 28 As clinical breakpoints depend on the clinical features of the disease and the dose regimen, we chose the epidemiological cut-off value of fosfomycin for E. coli to calculate the PD indices. This value is independent of the dose regimens and exclusively determined by the MIC values distribution and therefore not used to advise on clinical therapy. 41 In this regard, further studies are urgently needed to establish the PK-PD relationships of fosfomycin. Microbiological susceptibility information could also be included in Monte Carlo simulations in order to define oral dosing regimens based on potential PK/ PD targets with high probability of microbiological cure. This has been recently reported following intravenous infusion of fosfomycin in the treatment of Klebsiella pneumoniae, 42 and Pseudomonas aeruginosa.
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Literature review on fosfomycin PK and simulations clearly indicate the need for further clinical research to characterize the PK and PD properties of fosfomycin tromethamine. Previous studies reported potential decreased absorption at higher doses 24, 44 and fosfomycin recirculation. 24 In the model building, these concepts were considered but did not improve the descriptive properties of the model with regards to the available data. Also, when administering doses that are higher than the current recommended dose in the clinic, this may result in nonlinear PK. 24, 44 Hence, in the design of a future clinical trial, dose regimens as well as sampling times should be chosen to optimally address these potential PK characteristics.
Characterization of these processes is the key to the design of optimal multiple-dose strategies, as saturable absorption or elimination can limit the use of higher doses and recirculation can lead to clinically relevant accumulation.
Simulations and PD indices show that a total daily oral dose of at least 6-12 g of fosfomycin tromethamine are required to achieve a therapeutic concentration to treat systemic infections, based on the epidemiological cut-off value for E. coli. In light of the reported simulations, the population PK model can be used to optimize a new clinical trial to assess the PK, safety, and tolerability of fosfomycin tromethamine in multiple-dose regimens.
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